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SHORT COMMUNICATION
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T. Efferth', B. Lathan2 & M. Voim'
'German Cancer Research Centre, Institute ofExperimental Pathology, W-6900 Heidelberg; and 2Medical Clinic, University of
Cologne, W-5000 Cologne, Germany.
The development of drug resistance is a major problem in
effective chemotherapy of cancer. During the past few years,
the phenomenon of multidrug resistance (MDR) has been
described (Ling et al., 1983; Volm et al., 1987). Frequently,
MDR-cells overexpress a membrane protein (P-glycoprotein,
P-170) which is thought to function as an efflux pump for
different cytostatics and thereby cause the development of
drug resistance (Juliano & Ling, 1976; Chen et al., 1986).
P-glycoprotein could serve as a target for the selective killing
of MDR-cells. In an effort to devise an effective treatment
for drug-resistant tumours we have evaluated the therapeutic
potential of the monoclonal antibody (MAb) 265/F4 against
P-glycoprotein (Lathan et al., 1985) with regard to its ability
to inhibit growth of MDR-cells. Furthermore, we have con-
structed an immunotoxin by coupling ricin-alpha chain
(RAC) to MAb 265/F4. Our results indicate that MAb 265/
F4 and 265/F4-RAC conjugate may be important weapons
for the selective killing of MDR-cells.
-For this investigation sensitive and colchicine-resistant
Chinese hamster ovary (CHO) cells were used (obtained from
Dr V. Ling, Ontario Cancer Institute, Toronto, Canada). The
CHO-cells were cultured in a-MEM medium with ribonucleo-
sides and deoxyribonucleosides (Biochrom, Berlin, Germany)
supplemented with 10% foetal calf serum. The colchicine-
resistant subline (CHO-C5R) was maintained continuously in
the presence of 5 fig ml-' colchicine. The MDR-phenotype of
these cells has been reported earlier (Bech-Hansen et al.,
1976). The detection of P-glycoprotein by Western blotting
was carried out as described previously (Volm et al., 1989).
The inhibitory effect of MAb 265/F4 and MAb MRK 16,
respectively, was determined by measurement of cell growth.
For evaluation of cell number 5,000 cells per well were
seeded in 24-well tissue culture plates (Becton Dickinson,
Heidelberg, Germany). After 2 days the antibody at different
concentrations was added. Seven days after application the
cells were harvested and counted. For the analysis of preser-
vation of binding capability of the 265/F4-RAC conjugate
and of the presence of ricin the conjugate we used a
modified radioimmuno-assay originally described by Krolick
et al. (1980). Sensitive and resistant CHO-cells were seeded in
96-well microtitre plates (Becton Dickinson). After 6 days the
medium was removed, the cells were fixed in ethanol and
stored at - 20°C until examined. For blocking of non-specific
binding sites cells were preincubated with 1% bovine serum
albumine (Serva, Heidelberg, Germany) for 20 min at room
temperature. Thereafter, monoclonal antibody 265/F4 (3jig
ml-') and 265/F4-RAC immunotoxin (31ig ml-'), respective-
ly, were applied for 20 h at 4°C. Then, three rinsing steps
with phosphate buffered saline (PBS, pH 7.4) were done. For
detection of MAb 265/F4 the cells were incubated with bio-
tinylated sheep anti-mouse Ig (dilution 1:200, 30min; Amer-
sham, Braunschweig, Germany) at room temperature. For
detection of ricin rabbit anti-RAC antibody (dilution 1:400,
30min; Medac) followed by biotinylated donkey anti-rabbit
Ig (dilution 1:200, Dianova, Hamburg, Germany) were used.
After rinsing with PBS, 35S-labelled Streptavidin (dilution
1:200 (1.1 Ci mmol-', 30min; Amersham) was added. After
the cells were washed again, the wells were cut out and
measured in a scintillation counter. The covalent coupling of
monoclonal antibody 265/F4 to the A-chain of ricin followed
by the protocol of Krolick et al. (1983) with slight modifica-
tions. A stock solution of 30 mM Bolton Hunter reagent
(N-succininimidyl-3(2-pyridyldithio)proprionate (SPDP), Medac,
Hamburg, Germany) was prepared in dimethylformamide.
Five fil of this stock solution were added to 1 ml of MAb
265/F4 (1 mg ml-'), incubated for 30 min at room tempera-
ture, and dialysed for 60 min against 1 litre sodium acetate
buffer (50 mM sodium acetate, 150 mM NaCl, pH 4.5) in
order to remove unreacted SPDP. Prior to coupling of ricin-
alpha-chain (RAC) to 265/F4-SPDP conjugate, RAC (Medac)
was dialysed against 2 litres of cold acetate buffered saline
for 60min. Thereafter, ml of 265/F4-SPDP (1 mg) was
applied to 3.5 ml RAC (0.7 mg). The mixture was immedi-
ately dialysed against 1 litre of phosphate buffered saline
(pH 7.8) for 16-20 h at room temperature. The 265/F4-RAC
conjugates were separated from uncoupled RAC by gel filtra-
tion on a 1 cm x 50 cm Sephacryl S-200 column (Pharmacia,
Freiburg, Germany), equilibrated with PBS (pH 7.0) and
subsequently sterile filtered.
The specificity of MAb 264/F4 for P-glycoprotein was
demonstrated by Western-blotting. Membrane-fractions of
resistant CHO-cells revealed a single band of M, 170,000
(Figure 1, lane R) which was not detectable in membrane-
fractions of sensitive CHO-cells (Figure 1, lane S).
The binding capability of 265/F4-RAC conjugate and the
presence of ricin in the conjugate was tested by radio-
immuno-assay (Table I). 265/F4-RAC immunotoxin bound
strongly to resistant cells, whereas the binding to sensitive
cells was low. Thus, 265/F4-RAC is able to detect P-glyco-
protein in resistant CHO-cells. An anti-RAC antibody was
used to detect ricin in the conjugate. The c.p.m.-values
detecting RAC and MAb 265/F4 in the conjugate are com-
parable indicating that one ricin molecule is bound to one
antibody molecule. Since the coupling of RAC to antibodies
may reduce the binding ability to the target protein, we
compared the binding of265/F4-RAC and uncoupled 265/F4
to resistant CHO cells. As can be seen in Table I, there are
no differences in the reactivity between the immunotoxin and
the native antibody. In control measurements, the anti-RAC
antibody failed to detect uncoupled 265/F4 indicating the
specificity of the radioimmuno-reaction.
In order to examine whether MAb 265/F4 possesses an
inhibitory effect on cell growth, we exposed sensitive and
resistant CHO-cells to different concentrations of this anti-
body in drug-free medium. As can be seen in Figure 2a,
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Figure 1 Western blot analysis of P-glycoprotein (P-170) by
MAb 265/F4. Lane S: sensitive CHO-cells; Lane R: colchicine-
resistant CHO-cells. Each lane was loaded with 10 1g protein.
The working dilution of MAb 265/F4 was lO1igml-'.
Table I Analysis of265/F4-RAC immunotoxin and uncoupled MAb
265/F4 by radioimmuno-assay
I' antibody 2° antibody c.p.m. bound
Sensitive CHO:a 265/F4-RAC anti-mouse 1gb 546c
Resistant CHO: 265/F4-RAC anti-mouse Ig 4772
anti-RAC 4715
265/F4 anti-mouse Ig 5038
anti-RAC 319
a105 cells/well; bAn anti-mouse Ig to detect the antibody and an
anti-RAC antibody to detect ricin were used as secondary antibodies;
CMean values of 2-4 measurements.
MAb 265/F4 inhibited the growth of multidrug-resistant
CHO-cells in a dose-dependent manner. Maximal effect (75%
inhibition of growth) was observed at a concentration of
1OOLgml-l MAb 265/F4 after a 7-day exposure of the
antibody. In contrast to resistant cells, MAb 265/F4 had only
little effect on the growth of sensitive CHO-cells. We
measured a growth inhibition up to 20% as compared to
untreated control cells.
The antitumour activity of the 265/F4-RAC conjugate on
sensitive and multidrug-resistant CHO-cells is shown in
Figure 2b. Again, the growth of resistant cells could be
inhibited selectivity dependent on the concentration of 265/
F4-RAC conjugate. At a concentration of 3 gig ml ' cell
growth was reduced by 90%. In contrast, the same concen-
tration of immunotoxin caused only a growth inhibition of
10% in sensitive cells. In control experiments an inhibitory
effect of uncoupled ricin alpha chain was not observed (data
not shown).
Furthermore, we analysed the effect of MAb MRK 16
which detects P-glycoprotein in human cells, but not in CHO
cells on cell growth of sensitive and resistant CHO-cells. In
this experiment we proved whether a specific targetting of
Doses (,ug ml-')
Figure 2 a, Selective growth-inhibitory effect of MAb 265/F4
and b, 265/F4-ricin alpha chain (RAC) immunotoxic on col-
chicine-resistant CHO-cells. Samples each containing 5,000 cells
were seeded in 24-well culture plates. Two days later various
dilutions of MAb 265/F4 and 265/F4-RAC, respectively, were
applied and the cell number was counted after further incubation
for 7 days. Cell growth of sensitive (A A) and colchicine-
resistant CHO-cells (A--A) is expressed as percentage of
untreated controls. Each point represent the mean of four deter-
minations of one experiment. A repeated experiment showed
similar results.
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Figure 3 Effect of MAb MRK 16 on cell growth of sensitive
(A- ) and colchicine-resistant CHO-cells (A- --A). Details
see Figure 2.
P-glycoprotein is required to inhibit cell growth or whether
increased unspecific membrane turnover and protein inter-
nalisation in resistant cells result growth inhibition. As can
be seen in Figure 3, MAb MRK 16 had only marginal effect
on cell growth of both sensitive and resistant CHO cells.
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Thus far, several monoclonal antibodies (265/F4 (Lathan
et al., 1985); C219, C494 (Kartner et al., 1985), 32G7 (Danks
et al., 1985), MRK 16, MRK 17 (Hamada & Tsuruo, 1986),
JSB-1 (Scheper et al., 1988), HYB-612 (Meyers et al., 1989),
and polyclonal antibodies P7 (Richert et al., 1988), anti-P,
anti-C (Yoshimura et al., 1989), anti-PO, anti-P4, 4007, 4077
(Bruggemann et al., 1989)) against P-glycoprotein has been
prepared. However, only few of these antibodies (265/F4,
MRK 16, MRK17, and HYB-612) were developed against
intact tumour cells and recognised external epitopes of P-
glycoprotein. The external targetting of surface proteins by
monoclonal antibodies can be used for immunotherapeutical
approaches. Therefore, antibodies recognising external epi-
topes of P-glycoprotein might be suitable for an efficaceous
treatment of MDR-cells. Indeed, our results and the experi-
ments of Hamada and Tsuruo (1986) indicate that the anti-
bodies 265/F4, MRK 16 and MRK 17 possess biological
activity against MDR-cells in vitro. Both MRK 16 and MRK
17 have been used for the selective growth inhibition of
human MDR-tumours in nude mice (Tsuruo et al., 1989). In
contrast to the growth inhibitory feature of 265/F4, applica-
tion of this antibody to drug-containing medium showed that
265/F4 is unable to modulate drug accumulation (unpublish-
ed results). The biochemical mechanism of the selective
growth-inhibitory effect of MAb 265/F4 on multidrug-resis-
tant CHO-cells is until now unclear. We found a marginal
inhibition effect of MAb 265/F4 on sensitive CHO-cells.
MAb MRK 16 which does not cross-react with P-glyco-
protein of CHO-cells also inhibited growth of sensitive and
resistant cells to a small extent. We suggest that these mar-
ginal effects were not due to binding of P-glycoprotein. This
might reflect unspecific pinocytosis of MAb 265/F4 and MAb
MRK 16, respectively, together with culture medium.
Furthermore, we showed that a MAb 264/F4-ricin alpha
chain conjugate is able selectively to inhibit the growth of
multidrug-resistant CHO-cells. These data are in accordance
with Fitzgerald et al. (1987), who used MAb MRK 16
coupled to Pseudomonas exotoxin as immunotoxin to kill
multidrug-resistant KB-cells in vitro. Effective doses of MRK
16-Pseudomonas exotoxin are lower (1-10ngml-', Fitz-
gerald et al., 1987) than those of 265/F4-RAC (0.3-3ljg
ml-'). Similarly, biological activity of uncoupled MRK 16
was also observed at lower concentrations (1 lgml-',
Hamada & Tsuruo, 1986) as compared to uncoupled 265/F4
(10-I00 ig ml-'). This might reflect differences in the bind-
ing affinities of the two antibodies to P-glycoprotein. The
selective growth inhibition by MAb 265/F4 and 265/F4-RAC
immunotoxin in vitro raises the possibility. of using this
antibody for the treatment of human tumours which are
unresponsive to conventional therapy by doxorubicin or vin-
cristine. However, before such immunotoxicological approaches
for the treatment of MDR-cells can be established, several
problems remain to be solved. One substantial obstacle is the
expression of P-glycoprotein in certain normal tissues, e.g.
kidney, liver, colon and brain capillaries (Sugawara et al.,
1988). Nevertheless, the selective killing of MDR-cells by
265/F4 should encourage further investigation which may
provide guidelines for the improvement of conventional
chemotherapy.
We thank Dr T. Tsuruo for the generous provision of MRK 16. We
are indebted to Dr J.M. Walsh for critically reading the manuscript.
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